Ozempic Face: Causes, Evidence, Prevention, Fillers, Biostimulators and Skin Tightening (2026)

Last updated: October 2026

Have you noticed hollow cheeks, deeper smile lines, more visible wrinkles or loose skin after losing weight with Ozempic, Wegovy, Mounjaro or another GLP-1-based medication? These changes are commonly called Ozempic face.

The term describes an appearance rather than a formally defined disease. It generally refers to facial volume loss and skin laxity associated with substantial weight loss. Similar changes can occur following bariatric surgery, dietary weight loss and treatment with other weight-management medications.

The good news is that several options may improve facial appearance. The important distinction is between preventing avoidable nutritional and muscle losses, replacing lost facial volume and tightening loose skin. These are different problems and do not respond equally to the same treatment.

This guide reviews the available evidence, practical prevention strategies, hyaluronic acid fillers, collagen-stimulating biostimulators, energy-based skin tightening and surgical options. It also explains the risks that matter when choosing a cosmetic treatment.

Ozempic face: the key points

• Why it happens: Loss of facial fat during weight reduction can make the temples and cheeks look hollow and facial folds more prominent. Skin elasticity, age and baseline facial anatomy influence the result.
• Is it caused directly by semaglutide? The independent contribution of the drug, apart from weight loss, remains uncertain. It is not established that semaglutide uniquely damages facial skin.
• Can it be prevented? You can support skin and muscle health and avoid unnecessarily aggressive weight-loss practices, but no strategy has been proven to prevent all weight-loss-related facial volume loss.
• What works for lost volume? Carefully selected hyaluronic acid fillers, collagen-stimulating injectables or fat transfer may help, depending on the anatomy and the degree of volume loss.
• What works for loose skin? Certain energy-based procedures can produce modest improvements in selected patients. Significant excess skin may require surgery.
• What should you avoid? Unnecessary changes to prescribed medication, excessive filler, unqualified injectors and aggressive energy treatments that could worsen facial fat loss.

What is Ozempic face?

Ozempic face is a popular term for facial changes that become noticeable during or after substantial weight loss. The face contains superficial and deeper fat compartments that contribute to cheek projection, temple fullness, under-eye contours and support for overlying skin.

When these compartments lose volume, the face may appear less full. Skin that previously stretched over a fuller face can also look looser, especially when its elasticity has already declined with age.

Common changes include:

• Hollowing of the temples.
• Flatter or less full cheeks.
• More noticeable nasolabial folds, which run from the sides of the nose toward the corners of the mouth.
• Deeper marionette lines around the lower mouth.
• More prominent under-eye hollows in some people.
• Loose skin along the jawline or neck.
• Fine wrinkles or a crepey skin texture that may become more noticeable.

Not everyone taking a GLP-1 medication develops these changes. The appearance depends on how much weight is lost, baseline facial structure, age, genetics, skin quality and other individual factors.

What causes Ozempic face?

1. Loss of facial fat

Facial fat contributes to soft contours and structural support. As total body fat declines, facial fat can also decrease. Depending on the individual, the temples, cheeks and areas around the eyes may become more hollow.

The face does not necessarily lose fat uniformly. A person can achieve meaningful improvements in weight-related health while noticing changes in areas that previously contributed to a youthful or naturally full facial appearance.

2. Reduced skin elasticity and laxity

Skin does not always retract completely after the underlying volume decreases. Age, sun exposure, smoking history, genetics and pre-existing skin damage can influence how well skin adapts to a smaller facial contour.

Facial hollowing and skin laxity may occur together, but they are not interchangeable. A treatment that tightens skin cannot reliably replace substantial missing fat, while a filler may restore contour without removing significant excess skin.

3. Age, genetics and baseline facial anatomy

Older adults may be more likely to notice persistent looseness because skin elasticity changes with age. People who naturally have less facial fat may also notice contour changes sooner than those who begin with fuller cheeks.

These factors help explain why two people can lose a similar amount of weight yet have very different facial outcomes.

4. Weight-loss magnitude and rate

The amount of weight lost appears relevant. Research on facial changes after weight loss supports a relationship between greater weight reduction and more noticeable facial deflation.

However, an important distinction remains: the independent effect of weight-loss speed on Ozempic face has not been established clearly. Gradual, medically supervised weight loss is a sensible general approach, but it should not be promoted as a proven way to preserve facial fat.

5. Muscle and nutritional status

Substantial weight loss can involve loss of lean tissue as well as fat. Inadequate protein intake, poor overall nutrition and insufficient resistance exercise may complicate the preservation of muscle during weight reduction.

Maintaining muscle and meeting nutritional needs support general health, but there is no strong evidence that protein supplements, collagen supplements or resistance training can selectively prevent facial fat loss.

Ozempic Face Before and After

View source

View source

Close-up of lower face showing facial volume loss, skin laxity and fine lines associated with rapid weight loss and ‘Ozempic face (view source)

What does the medical evidence say about Ozempic face?

The evidence is growing, but it is important to distinguish observations about facial changes during weight loss from proof that a particular medicine directly damages facial tissue.

A review published in the Aesthetic Surgery Journal on October 14, 2026, searched several medical literature databases for studies published from January 2014 through August 2026. Of 958 records identified, 46 reports were included.

The review reported the following findings:

• A small serial-imaging study of 20 patients found a median 9% reduction in midfacial volume. The reported reduction was greater in superficial than deeper facial fat compartments.
• A regression analysis estimated approximately 7% lower total midfacial volume per 10 kg of weight lost.
• A survey of 1,226 participants found that reports of facial volume loss and skin laxity increased with greater percentage weight loss.
• Evidence from post-bariatric populations also supports the occurrence of facial deflation following substantial weight loss.

These figures provide context, not a personal prediction. The imaging sample was small, and the findings do not establish that everyone will experience the same amount of facial volume loss or that semaglutide itself caused all observed changes.

The authors concluded that weight-loss-associated facial deflation, combined with pre-existing anatomy and aging, is the explanation best supported by the available evidence. Evidence for specific cosmetic treatments remains limited and is largely uncontrolled.

Primary research source: Glucagon-Like Peptide-1 Receptor Agonist-Associated Facial Changes: A Comprehensive Review of Pathophysiology, Clinical Manifestations, Risk Factors, Prevention, and Management.

The American Academy of Dermatology also discusses facial fullness, sagging skin and wrinkles reported during GLP-1-associated weight loss. Its patient guidance describes potential cosmetic options but does not establish a single treatment as best for everyone.

Read: American Academy of Dermatology: How GLP-1 drugs can affect skin, hair and nails.

Evidence summary

Claim	Evidence assessment	Practical interpretation
Substantial weight loss can reduce facial volume	Supported by imaging and observational evidence	Facial contour changes are a plausible consequence of weight loss.
Ozempic uniquely causes facial aging independent of weight loss	Not established	Do not assume the medicine is directly damaging the skin or facial fat.
Rapid weight loss specifically causes more Ozempic face than gradual loss	Uncertain	Avoid unsupported promises about a particular rate preventing facial changes.
Protein and resistance exercise prevent facial fat loss	Not demonstrated	They support general nutrition and muscle preservation, not selective facial-fat preservation.
Fillers and selected cosmetic procedures can improve appearance	Evidence exists for specific cosmetic indications; direct Ozempic-face evidence is limited	Choose treatment according to the actual anatomical problem.

How to prevent or reduce Ozempic face

There is currently no proven protocol that guarantees facial-volume preservation during GLP-1 treatment. The following measures focus on general health, muscle preservation and avoiding preventable problems.

1. Discuss an appropriate weight-loss plan with your prescriber

Weight loss should be planned around your medical needs, treatment response, nutritional status and tolerance. Do not increase the dose faster than prescribed or restrict food excessively in an attempt to accelerate results.

The CDC notes that people who lose weight gradually, at around 1–2 pounds per week, are more likely to maintain weight loss than those who lose it more quickly. This is general weight-management guidance, not an established facial-preservation target for people taking GLP-1 medications. Individual treatment plans may differ.

Do not reduce, delay or stop Ozempic, Wegovy, Mounjaro or another prescribed treatment purely to change your facial appearance without discussing the decision with your prescriber.

Reference: CDC: Steps for Losing Weight.

2. Preserve muscle with appropriate resistance exercise

Resistance training can support strength and lean-mass preservation during weight loss. A suitable programme may include progressive strength exercises for the major muscle groups, adapted to your fitness, mobility and medical circumstances.

Exercise does not selectively preserve facial fat. Its value is in supporting overall body composition, function and long-term health.

3. Meet your protein and nutritional needs

Appetite suppression can make it harder to eat enough. Prioritise adequate meals and a balanced dietary pattern that supplies protein, essential fats, vitamins and minerals.

Your protein requirements depend on factors such as age, activity, total energy intake, body composition and kidney function. A clinician or dietitian can help establish an appropriate intake, particularly if you have kidney disease or another condition requiring dietary restrictions.

Collagen powders, multivitamins and other supplements should not be marketed as proven Ozempic-face prevention. Supplementation is most useful when there is a nutritional need or a specific clinical indication.

4. Protect skin quality

Daily broad-spectrum sunscreen, moisturiser and a suitable skincare routine can support the skin barrier and help limit some forms of sun-related skin damage. A clinician may recommend a topical retinoid for certain signs of photoaging if it is appropriate for you.

Skincare cannot restore a lost deep-fat compartment or remove substantial loose skin. Avoid confusing improved skin texture with restoration of facial volume.

5. Document changes before considering treatment

Standardised photographs taken in consistent lighting and at similar angles can make gradual changes easier to assess. Discuss facial changes during routine follow-up, especially if weight loss has been substantial or your diet has become difficult to maintain.

Early assessment does not mean you need immediate filler or surgery. It helps establish whether the dominant issue is volume loss, wrinkles, skin laxity or a combination.

6. Avoid aggressive treatment before understanding the problem

Not every hollow or wrinkle needs an injectable. Excessive filler can create an unnatural appearance, while aggressive energy-based treatments may not be appropriate for a face that has already lost volume.

When weight is still changing, a clinician can help determine whether it is reasonable to observe the evolving contour or consider a conservative interim procedure.

Ozempic face treatment: fillers vs biostimulators vs skin tightening

The best treatment depends on the main concern. Restoring volume, stimulating collagen, improving surface texture and removing excess skin are different goals.

Hyaluronic acid fillers

Best suited to: Selected areas of lost volume or contour definition.

Main advantage: Immediate correction with adjustable results; many hyaluronic acid fillers can be dissolved using hyaluronidase when clinically appropriate.

Main limitation: Temporary results and procedure-related risks. Fillers do not remove substantial loose skin.

Biostimulators

Best suited to: Selected patients seeking gradual volume improvement and collagen stimulation.

Main advantage: Results develop over time and may last longer than some conventional fillers.

Main limitation: Results are not immediate, suitability is product- and site-specific, and some products are difficult to reverse.

Skin-tightening procedures

Best suited to: Selected cases of mild skin laxity, depending on the device and anatomical area.

Main advantage: May improve firmness, texture or selected wrinkles without adding filler volume.

Main limitation: Results are variable and often modest. Some energy-based procedures can also cause unwanted facial fat loss or other complications.

Fat transfer or surgery

Best suited to: Selected cases of more substantial volume loss or persistent excess skin.

Main advantage: Can address anatomical changes that non-surgical treatments cannot fully correct.

Main limitation: Greater cost, recovery, procedural risk and, for fat transfer, variable fat retention.

1. Hyaluronic acid fillers for Ozempic face

Hyaluronic acid (HA) fillers are gel-based injectables used to restore volume or improve contour in selected facial areas. They may be considered when loss of cheek projection, temple fullness or other appropriate facial volume makes the face look hollow.

Potential benefits

• Visible volume correction soon after treatment.
• Ability to make conservative, targeted changes to facial contour.
• Many HA products can be dissolved with hyaluronidase if correction is necessary, although dissolving filler is itself a medical intervention and does not eliminate all risks.
• The clinician can generally evaluate the result before deciding whether further correction is appropriate.

Limitations

• Results are temporary, and repeat treatment may be needed.
• Fillers can cause swelling, bruising, asymmetry, lumps or an overfilled appearance.
• They do not correct significant skin excess or all aspects of facial aging.
• Filling one area without assessing the entire face can produce poor proportions.

The safest approach is generally an anatomy-led plan rather than filling every visible crease. The location, depth, product and volume should be selected by a qualified medical professional with appropriate training in facial anatomy and filler complications.

Read: FDA: Dermal Fillers and Their Risks.

2. Biostimulators: Sculptra, Radiesse and related products

Biostimulatory injectables are intended to stimulate a tissue response, including collagen production, rather than relying only on the immediate volume of a gel. They are not interchangeable products, and their indications, techniques, expected results and reversibility differ.

Poly-L-lactic acid (PLLA): Sculptra

PLLA is a collagen-stimulating injectable. Improvement develops gradually, and treatment may require a series of sessions rather than a single immediate correction.

The FDA's April 2023 approval expansion for Sculptra includes correction of fine lines and wrinkles in the cheek region in immunocompetent adults. Its published information indicates that results may last up to 24 months, although individual outcomes vary. This does not mean every use for facial volume loss or every injection site has the same indication.

Important considerations include:

• Results develop over weeks to months rather than appearing immediately.
• Several sessions may be needed.
• Swelling, bruising, lumps and delayed nodules are possible.
• PLLA is not simply dissolved in the same way as an HA filler.
• Appropriate product selection, reconstitution, injection technique and follow-up matter.

FDA source: Sculptra: FDA approval information.

Calcium hydroxylapatite (CaHA): Radiesse

Calcium hydroxylapatite is another injectable material that can provide immediate structural correction and stimulate collagen-related tissue responses. Its suitability depends on the treatment area, facial anatomy and the product's authorised indications.

CaHA is not routinely reversible with a simple dissolving agent in the way an HA filler may be. Patients should understand this distinction before treatment.

It may be appropriate in selected patients, but it should not automatically be regarded as superior to HA fillers simply because collagen stimulation is a treatment goal.

Polycaprolactone (PCL) and other collagen-stimulating injectables

Other products are marketed for long-lasting volume correction or collagen stimulation. Product approval, availability and supporting clinical evidence vary by country and formulation.

Do not assume that all products called biostimulators have equivalent safety data, regulatory status or reversibility. Ask for the exact product name, its authorised indication, its expected duration and the plan for managing complications.

Are biostimulators better than HA fillers for Ozempic face?

There is not enough high-quality, direct comparative research in GLP-1-associated facial changes to declare one injectable universally best.

HA fillers may be useful when a clinician wants targeted, immediate and potentially reversible contour correction. A biostimulator may be considered when gradual improvement is appropriate and the patient accepts delayed results and limited reversibility.

The decision should be based on the patient's facial anatomy and goals, not on a general claim that one material produces better collagen or a more natural result for everyone.

3. Skin tightening: radiofrequency, ultrasound and laser treatments

Energy-based procedures can help some patients with selected aspects of skin laxity, wrinkles or texture. Their effects depend on the device, treatment depth, settings, operator and patient's anatomy.

Radiofrequency (RF)

Radiofrequency devices deliver energy to tissue, producing heating intended to trigger a tissue response and improve selected signs of skin aging. Some clinical studies report improvements in skin firmness or wrinkles, but the magnitude and durability of results vary.

An important safety distinction: RF treatment should not automatically be considered an ideal first-line treatment for a face that already looks hollow. Some RF approaches can reduce facial fat, which may be undesirable when the central problem is volume depletion.

RF microneedling: an important safety warning

On October 15, 2025, the US Food and Drug Administration issued a safety communication about serious complications reported with certain uses of RF microneedling devices for aesthetic procedures. Reported complications included burns, scarring, disfigurement, fat loss, nerve damage and the need for surgical repair or other medical intervention.

This warning does not mean that every RF device or every appropriately performed treatment causes such complications. It does mean that patients should not treat RF microneedling as a risk-free routine facial procedure.

Before considering it, ask whether the specific device and proposed settings are appropriate for your facial anatomy, how the clinician will minimise unwanted fat loss and what experience the clinician has managing complications.

Reference: FDA: Potential Risks with Certain Uses of RF Microneedling.

Ultrasound-based skin tightening

Selected ultrasound-based devices are used to target tissue at defined depths and may provide modest lifting or tightening in appropriately selected patients.

They do not replace lost fat, and they cannot reliably correct significant excess skin. Device choice, treatment area, technique and individual anatomy influence results. Ask about the specific device's authorisation, expected degree of improvement and potential complications.

Laser resurfacing and other light-based treatments

Some laser treatments can improve fine wrinkles, uneven texture and signs of sun damage. Their primary role is often skin quality rather than replacing substantial facial volume or correcting major laxity.

Downtime, pigmentation changes, scarring and other risks depend on the device, settings and individual skin characteristics. A dermatologist should assess suitability, particularly for skin types more prone to post-inflammatory pigmentation.

What does the evidence say about skin tightening?

A systematic review published in 2025 examined radiofrequency-based facial rejuvenation studies published from 2015 through 2025. It reported improvements in selected aesthetic outcomes, including skin texture and firmness. However, evidence from general facial rejuvenation studies cannot establish how well a particular treatment works specifically for Ozempic face.

These procedures should therefore be considered selective options rather than proven methods for reversing GLP-1-associated facial changes.

Research: Radiofrequency-Based Treatments for Facial Rejuvenation: A Systematic Review of Efficacy, Safety, and Patient-Centered Outcomes.

4. Fat transfer for facial volume restoration

Autologous fat transfer involves removing fat from one area of the body, processing it and injecting it into selected facial areas.

Potential advantages include the use of the patient's own tissue and the possibility of longer-lasting correction in some patients. However, some transferred fat may not survive, and additional treatment may be necessary.

Fat transfer is a surgical procedure, not a simple skincare treatment. Risks include infection, asymmetry, irregular contour, fat necrosis and complications related to injection or surgery. Careful assessment and an experienced appropriately qualified surgeon are essential.

Fat transfer may be considered when more substantial volume restoration is desired, but it is not automatically better than HA fillers or biostimulators. The choice depends on the amount and location of volume loss, available donor fat, medical history and treatment preferences.

5. Facelift and other surgical options for substantial skin laxity

When the dominant problem is substantial loose skin, injectable fillers and energy-based procedures may be insufficient.

Selected patients may benefit from surgical procedures such as a facelift, neck lift or other anatomically appropriate operations. These procedures can address excess skin and reposition tissues more directly, but they involve recovery, scarring, anaesthesia and surgical risks.

For patients who are still losing significant weight, it may be sensible to discuss timing carefully. Further changes in body weight and facial volume may affect cosmetic results. There is no single waiting period that is appropriate for everyone.

If you take a GLP-1 medication and are planning surgery, tell the surgical and anaesthesia teams. Follow their individual medication and fasting instructions rather than stopping a prescribed drug independently.

Which Ozempic face treatment is best for you?

A useful starting point is to identify which problem contributes most to the appearance you want to change.

Main concern	Options to discuss	Important limitation
Hollow cheeks or selected facial volume deficits	HA fillers, selected biostimulators or fat transfer	Not all products or injection sites are suitable for every patient.
Gradual loss of fullness with selected contour concerns	PLLA or CaHA where appropriate	Delayed results, product-specific risks and limited reversibility must be considered.
Mild skin laxity	Selected RF or ultrasound procedures	Benefits may be modest, and unwanted fat loss or other complications are possible with certain treatments.
Fine wrinkles and uneven skin texture	Appropriate skincare or selected laser procedures	Improving texture does not restore deep facial volume.
Substantial loose skin or marked structural changes	Assessment by a qualified plastic surgeon	Surgery involves greater cost, recovery and risk.

Some people have more than one issue and may benefit from a staged combination of treatments. The sequence matters: adding volume to selected areas, improving skin quality and addressing excess skin are separate decisions.

When weight is still changing, discuss whether it is better to observe the evolving facial contour or make a conservative correction. Avoid committing to extensive treatment based on assumptions about how your face will look once weight stabilises.

Safety: what to know before cosmetic treatment

Dermal fillers are medical procedures

Although many patients tolerate fillers well, serious complications can occur. Accidental injection into a blood vessel can obstruct blood supply and cause skin necrosis, visual impairment including blindness, or stroke. These events are uncommon but potentially devastating.

Ask the clinician about their training, the exact product to be used, the product's authorised indication, potential complications, follow-up and emergency management plan. Product approval and professional regulation differ between countries.

Seek immediate emergency medical attention if you develop unusual or severe pain, skin that turns white, grey or blue, sudden visual changes or symptoms suggestive of a stroke during or after filler injection.

Read the FDA's dermal filler safety guidance before making a decision.

Do not assume every injectable is reversible

Many HA fillers can be dissolved with an enzyme, but this is not a guarantee that every complication can be completely reversed. PLLA, CaHA, PCL and permanent fillers have different properties and may require different approaches when adverse effects occur.

A proposed treatment should include a discussion of what happens if the outcome is unsatisfactory, how complications are managed and whether the material can be removed or reduced.

Avoid unapproved products and unqualified injectors

Do not purchase injectable fillers for self-injection or accept treatment using unidentified products. Injectable silicone for facial volume enhancement is not an appropriate substitute for an authorised facial filler and can cause serious harm.

Frequently asked questions about Ozempic face

Is Ozempic face permanent?

Not necessarily. Facial appearance can change as weight stabilises, but lost facial fat may not return fully on its own. Skin laxity and baseline age-related changes can persist. The likely degree of recovery varies, and there is no reliable way to predict an individual's final appearance from the amount of weight lost alone.

Does everyone taking Ozempic or Wegovy develop facial aging?

No. The effect varies substantially between individuals. Total weight loss, baseline facial fullness, skin elasticity, age and other personal factors influence the result.

Can I prevent Ozempic face by losing weight more slowly?

There is not enough direct evidence to promise that a slower rate will prevent facial-volume loss. A medically appropriate weight-loss plan, adequate nutrition and muscle-preserving exercise remain sensible for general health. Any medication or dose changes should be guided by your prescriber.

Do collagen supplements prevent facial hollowing?

There is no strong clinical evidence that collagen supplements prevent facial-fat loss caused by weight reduction. Supplements may have other effects depending on the product and outcome studied, but they should not be presented as a proven Ozempic-face prevention treatment.

Is filler better than a biostimulator?

Neither is universally better. HA fillers often provide immediate, targeted correction and many can be dissolved. Biostimulators work more gradually and are not equally reversible. Your facial anatomy, desired outcome, tolerance for risk and the product's authorised indications should guide the decision.

Can skin tightening make Ozempic face worse?

Some energy-based treatments may cause unwanted facial fat loss, and the FDA has warned about serious complications from certain uses of RF microneedling. This does not mean every tightening procedure is unsuitable, but patients with existing facial volume loss should have their anatomy assessed carefully before treatment.

Should I stop taking semaglutide because my face looks older?

Do not discontinue or change a prescribed medication solely on the basis of appearance without discussing the benefits, risks and alternatives with your healthcare professional. The decision should consider the reason for treatment, your health outcomes, side effects and preferences.

When should I consider fillers or surgery?

There is no universal timeline. If your weight is changing rapidly, your facial contour may continue to evolve. A qualified dermatologist or plastic surgeon can assess whether observation, a conservative injectable treatment, a skin procedure or surgical consultation is appropriate.

The bottom line

Ozempic face is a useful term for a real cosmetic concern, but it can be misleading when it implies that semaglutide uniquely damages the face. The current evidence more strongly supports facial-volume loss associated with weight reduction, interacting with age, skin elasticity and baseline facial anatomy.

Prevention should focus on a medically appropriate weight-loss plan, sufficient nutrition, muscle preservation and realistic expectations—not unproven supplements or unsupervised changes to medication.

For treatment, match the intervention to the problem. HA fillers and selected biostimulators may address volume loss; carefully chosen skin procedures may improve selected signs of laxity or wrinkles; fat transfer and surgery may be options for more substantial anatomical changes. None is risk-free, and no single procedure is best for everyone.

Editorial note: This article is for educational purposes and is not a substitute for an individual medical assessment. Evidence specifically addressing prevention and treatment of GLP-1-associated facial changes remains limited.

References and further reading

1. Yoo KH. Glucagon-Like Peptide-1 Receptor Agonist-Associated Facial Changes: A Comprehensive Review of Pathophysiology, Clinical Manifestations, Risk Factors, Prevention, and Management. Aesthetic Surgery Journal. Published October 14, 2026.
2. American Academy of Dermatology. How GLP-1 drugs can affect skin, hair and nails.
3. US Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers).
4. US Food and Drug Administration. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling.
5. US Food and Drug Administration. Sculptra: FDA approval information.
6. Centers for Disease Control and Prevention. Steps for Losing Weight.
7. Radiofrequency-Based Treatments for Facial Rejuvenation: A Systematic Review of Efficacy, Safety, and Patient-Centered Outcomes.
8. FDA — Wegovy (semaglutide) Prescribing Information, 2026. Hair loss is reported in adults receiving Wegovy 2.4 mg and is described as associated with weight reduction. View FDA label.
9. FDA — Zepbound (tirzepatide) Prescribing Information, 2026. Hair loss is reported in clinical trials and is described as associated with weight reduction. View FDA label.
10. FDA — Ozempic (semaglutide) Prescribing Information, revised 2025. Current highlighted information lists the principal common adverse reactions and does not identify hair loss as a common adverse reaction. View FDA label.
11. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002. DOI: 10.1056/NEJMoa2032183. PubMed.
12. Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes, Obesity and Metabolism. 2025;27:2720-2729. DOI: 10.1111/dom.16275. PubMed.
13. Soft Tissue Facial Changes Following Massive Weight Loss Secondary to Medical and Surgical Bariatric Interventions: A Systematic Review. 2024. PubMed.
14. Barişkan S, et al. Losing Weight and Gaining Wrinkles: The Impact of Weight Loss Drugs on Facial Aesthetics. 2026. DOI: 10.1097/SCS.0000000000012582. PubMed.
15. Frank K, et al. GLP-1-Induced Weight Loss and the Face. Dermatologic Surgery. 2026. DOI: 10.1097/DSS.0000000000005180. PubMed.
16. Alopecia as an Emerging Adverse Effect Associated With GLP-1 Receptor Agonists for Weight Loss: A Scoping Review. 2025. PubMed.
17. American Academy of Dermatology — How can GLP-1 drugs affect my skin, hair, and nails? Updated 2026. AAD.
18. American Academy of Dermatology — Do you have hair loss or hair shedding? Guidance on telogen effluvium and stress-related shedding. AAD.
19. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. 2026. PubMed.

Related OneDayMD Resources

GLP-1 Knowledge graph: GLP-1 & Peptide Hub → Starting GLP-1 → muscle loss → bone density → nutrient monitoring → stopping GLP-1 → personalizing treatment → Next generation (GLP 2.0)